Immunoglobulins

Often an indicator of fibrosis or damage to the heart, late gadolinium enhancement was found to be unaffected by the administration of intravenous immunoglobulin (IVIG) in pediatric patients with myocarditis.

These results provide a pediatric lens into the potential risk of thromboembolic events in patients with dermatomyositis.

An infusion and specialty clinical pharmacist is a valuable integrated member of the health care team as demonstrated by cost avoidance and high satisfaction reported by both veterans and specialty providers.

A series of patient cases demonstrates the potential harm that patients with chronic inflammatory demyelinating polyneuropathy (CIDP) may face when transitioning from intravenous immunoglobulin (IVIG) to FcRn therapy.

Admissions to the hospital for fever were reduced in pediatric patients with medium-risk ALL receiving intravenous immunoglobulin, a potentially useful finding to help prevent infections in vulnerable patients.

Managing comorbidities, ensuring proper dosing, and treating IVIG-related adverse events are areas where pharmacists play a large role.

For patients with multiple myeloma who may experience an infection while receiving teclistamab, supplementation with intravenous immunoglobulin (IVIG) can help resolve and prevent serious complications.

Treatment with IVIG leads to high responses 6 months following the initiation of therapy.

Factors associated with intravenous immunoglobulin (IVIG)-related adverse events include older age, dehydration, and administration of multiple IVIG infusions.

Pharmacists are encouraged to work closely with health care providers to ensure appropriate use of high-cost Intravenous immunoglobulin (IVIG) therapy for BK nephropathy.

Pharmacists can optimize IVIG treatment for BK nephropathy in kidney transplant recipients by educating providers and monitoring for infusion reactions.

Higher costs of efgartigimod alfa are primarily driven by its status as a newly approved, brand-name therapy without a generic alternative.

Often used as a treatment for severe exacerbations of myasthenia gravis, intravenous immunoglobulin can lead to high financial toxicity and resource utilization.

The management of MDS is primarily targeted at controlling or slowing the disease and preventing future complications as much as possible.

A vast majority of patients achieved a positive clinical response with the combination, with improvements in their ocular condition.

Knowledge of recent intravenous immunoglobulin (IVIG) administration in patients receiving the common laboratory test can help inform misdiagnosis.

Intravenous immunoglobulin (IVIG) has proven efficacy in autoimmune neuropathies, with mixed but promising outcomes in severe COVID-19 cases and post-acute sequelae of SARS-CoV-2 infection trials.

No acute serious bacterial infections were observed in a trial of patients with the debilitating immune disorder, a strong mark of safety and tolerability.

IVIG was found to cease development of new lesions and heal previously documented erosions without adverse events to the patient or fetus.

Efforts include a mandatory intravenous immunoglobulin ordering form, blood bank gatekeeping, and a stewardship committee to ensure optimized use.

Intravenous immunoglobulin prescriptions deemed non-compliant according to French national guidelines were more common in younger patients.

Utilizing data from the CHAMPION MG trial, investigators found that many patients had responded to ravulizumab and returned to daily activities within 2 weeks.

Therapy-related complications, in addition to financial obstacles, can complicate myasthenia gravis treatment.

Recognizing repeat dosing efforts is important to improving outcomes in patients with Guillain-Barré syndrome who do not respond to IVIG.

Glucocorticoids improved outcomes for patients with Kawasaki disease at high risk of IVIG resistance without glucocorticoid-related adverse effects.